LAVAL, Quebec, March 19, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti") (TSX-V:APO) (Nasdaq:ACST), a Neptune Technologies & Bioressources Inc. (" Neptune") subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 (CaPre ®) in the treatment of mild-to-high hypertriglyceridemia" (Open-label). In the course of planning the strategy of its phase III clinical development with CaPre ®, Acasti examined triglycerides data from its Open-label clinical trial. Data from 157 patients who have completed four weeks of treatment with 0.5, 1, 2 or 4 grams of CaPre ® per day were assessed and CaPre ® achieved a clinically important and statistically significant triglyceride reduction of up to 23% (p < 0.05) as compared to standard of care, after only a 4-week treatment. Moreover, a noteworthy trend indicating a dose-response relationship versus standard of care as well as clinically and statistically significant effects of doubling the doses of CaPre® were observed. It should also be noted that the study assesses the effectiveness of CaPre® in a real-life, routine - clinical setting since the standard of care may be any treatment the treating physicians considered as appropriate and included life-style modification as well as lipid modifying agents such as statins and fibrates, that most of the patients analysed (i.e. 86%) had baseline triglycerides between 200 and 500mg/dl (2.28 to 5.7 mmol/L) and that no serious adverse events were reported.
Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts